CSIQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Canadian Solar Inc (CSIQ) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance is weak, with significant YoY declines in revenue, net income, and gross margin. Analysts' ratings are mixed, with multiple firms lowering price targets and maintaining neutral or sell ratings. While the company has long-term potential due to its U.S. manufacturing expansion and leadership in solar energy, the current market sentiment and technical indicators suggest a cautious approach. For an impatient investor, this stock does not present an optimal entry point right now.
The technical indicators are mixed. The MACD is positive and expanding, which is a bullish signal, but the RSI is neutral at 45.851, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 12.985, with resistance levels at 13.921 and 14.499, and support levels at 12.049 and 11.471. Overall, the technical setup does not strongly favor a buy at this time.
Canadian Solar is expanding its U.S. manufacturing capacity, targeting 10 GWp of module capacity by 2H26 and 6.3 GWp of domestic solar cell capacity by year-end.
The company has a strong global presence, having delivered over 174 GW of solar photovoltaic modules and 18 GWh of battery energy storage solutions.
Weak Q4 2025 financials, with revenue down 19.99% YoY and net income down 354.66% YoY.
Analysts have lowered price targets significantly, citing headwinds such as higher input costs, limited supply of non-Prohibited Foreign Entity cells, and weak Q1 guidance.
The stock has a 60% chance of declining in the next week based on candlestick pattern analysis.
In Q4 2025, Canadian Solar's revenue dropped by 19.99% YoY to $1.217 billion. Net income fell sharply by 354.66% YoY to -$86.338 million, and EPS dropped by 354% YoY to -1.27. Gross margin also declined by 28.38% YoY to 10.22%. These metrics indicate significant financial challenges.
Analyst sentiment is mixed but leans negative. While Freedom Capital upgraded the stock to Buy with a price target of $16, other firms like Goldman Sachs and Mizuho have lowered their price targets to $11 and $15, respectively, citing weak financials and near-term headwinds. The average sentiment suggests caution, with no strong consensus for a buy.
